50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,636.45 (-2.22%)
DOW   29,176.82 (-1.71%)
QQQ   270.75 (-3.28%)
AAPL   142.40 (-4.97%)
MSFT   235.62 (-2.26%)
META   137.29 (-3.05%)
GOOGL   96.43 (-3.62%)
AMZN   114.31 (-3.14%)
TSLA   268.08 (-6.86%)
NVDA   120.82 (-5.14%)
NIO   15.59 (-10.04%)
BABA   78.40 (-3.20%)
AMD   63.82 (-6.64%)
T   15.53 (-1.90%)
MU   49.90 (-2.16%)
CGC   2.82 (-7.24%)
F   11.46 (-5.91%)
GE   62.34 (-3.29%)
DIS   96.98 (-2.43%)
AMC   7.10 (-7.43%)
PYPL   88.91 (-2.43%)
PFE   44.21 (-0.50%)
NFLX   238.64 (-2.68%)
S&P 500   3,636.45 (-2.22%)
DOW   29,176.82 (-1.71%)
QQQ   270.75 (-3.28%)
AAPL   142.40 (-4.97%)
MSFT   235.62 (-2.26%)
META   137.29 (-3.05%)
GOOGL   96.43 (-3.62%)
AMZN   114.31 (-3.14%)
TSLA   268.08 (-6.86%)
NVDA   120.82 (-5.14%)
NIO   15.59 (-10.04%)
BABA   78.40 (-3.20%)
AMD   63.82 (-6.64%)
T   15.53 (-1.90%)
MU   49.90 (-2.16%)
CGC   2.82 (-7.24%)
F   11.46 (-5.91%)
GE   62.34 (-3.29%)
DIS   96.98 (-2.43%)
AMC   7.10 (-7.43%)
PYPL   88.91 (-2.43%)
PFE   44.21 (-0.50%)
NFLX   238.64 (-2.68%)
S&P 500   3,636.45 (-2.22%)
DOW   29,176.82 (-1.71%)
QQQ   270.75 (-3.28%)
AAPL   142.40 (-4.97%)
MSFT   235.62 (-2.26%)
META   137.29 (-3.05%)
GOOGL   96.43 (-3.62%)
AMZN   114.31 (-3.14%)
TSLA   268.08 (-6.86%)
NVDA   120.82 (-5.14%)
NIO   15.59 (-10.04%)
BABA   78.40 (-3.20%)
AMD   63.82 (-6.64%)
T   15.53 (-1.90%)
MU   49.90 (-2.16%)
CGC   2.82 (-7.24%)
F   11.46 (-5.91%)
GE   62.34 (-3.29%)
DIS   96.98 (-2.43%)
AMC   7.10 (-7.43%)
PYPL   88.91 (-2.43%)
PFE   44.21 (-0.50%)
NFLX   238.64 (-2.68%)
S&P 500   3,636.45 (-2.22%)
DOW   29,176.82 (-1.71%)
QQQ   270.75 (-3.28%)
AAPL   142.40 (-4.97%)
MSFT   235.62 (-2.26%)
META   137.29 (-3.05%)
GOOGL   96.43 (-3.62%)
AMZN   114.31 (-3.14%)
TSLA   268.08 (-6.86%)
NVDA   120.82 (-5.14%)
NIO   15.59 (-10.04%)
BABA   78.40 (-3.20%)
AMD   63.82 (-6.64%)
T   15.53 (-1.90%)
MU   49.90 (-2.16%)
CGC   2.82 (-7.24%)
F   11.46 (-5.91%)
GE   62.34 (-3.29%)
DIS   96.98 (-2.43%)
AMC   7.10 (-7.43%)
PYPL   88.91 (-2.43%)
PFE   44.21 (-0.50%)
NFLX   238.64 (-2.68%)
CVE:ZOM

Zomedica Pharmaceuticals Corp. (ZOM.V) - ZOM Stock Forecast, Price & News

C$0.28
-0.02 (-6.56%)
(As of 02/5/2020)
Add
Compare
Today's Range
C$0.29
C$0.29
50-Day Range
C$0.29
C$0.29
52-Week Range
C$0.29
C$1.50
Volume
4,800 shs
Average Volume
2,858 shs
Market Capitalization
C$36.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ZOM stock logo

About Zomedica Pharmaceuticals Corp. (ZOM.V) (CVE:ZOM) Stock

Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. The company is also developing ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. It has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was founded in 2015 and is headquartered in Ann Arbor, Michigan.

Receive ZOM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zomedica Pharmaceuticals Corp. (ZOM.V) and its competitors with MarketBeat's FREE daily newsletter.

ZOM Stock News Headlines

Why Zomedica Stock Soared 72.4% This Week
Antarctic glacier named after Glasgow as Cop26 begins
Beware of These 4 Overvalued Reddit Stocks
Should You Buy Zomedica in April?
Is Zomedica a Buy?
Should You Buy Zomedica Stock in March?
Why Zomedica Stock Dropped Today
See More Headlines
Receive ZOM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zomedica Pharmaceuticals Corp. (ZOM.V) and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
27
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
C$0.05 per share
Book Value
C$0.05 per share

Miscellaneous

Free Float
N/A
Market Cap
C$36.73 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Gerald L. Solensky Jr. (Age 45)
    Chairman, Pres & CEO
  • Mr. Shameze Rampertab B.Sc. MBA (Age 52)
    CA, CPA, CFO, Corp. Sec. & Director
  • Dr. Stephanie Morley D.V.M. (Age 44)
    DVM, COO & VP of Product Devel.
  • Mr. Michael Schilk
    VP of Sales
  • Mr. David Eaton
    VP of Marketing













ZOM Stock - Frequently Asked Questions

How have ZOM shares performed in 2022?

Zomedica Pharmaceuticals Corp. (ZOM.V)'s stock was trading at C$0.29 at the start of the year. Since then, ZOM stock has increased by 0.0% and is now trading at C$0.29.
View the best growth stocks for 2022 here
.

What other stocks do shareholders of Zomedica Pharmaceuticals Corp. (ZOM.V) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zomedica Pharmaceuticals Corp. (ZOM.V) investors own include Heat Biologics (HTBX), Biocept (BIOC), Remark (MARK), Onconova Therapeutics (ONTX), Vislink Technologies (VISL), Genius Brands International (GNUS), Ritter Pharmaceuticals (RTTR), T2 Biosystems (TTOO), Guardion Health Sciences (GHSI) and MicroVision (MVIS).

What is Zomedica Pharmaceuticals Corp. (ZOM.V)'s stock symbol?

Zomedica Pharmaceuticals Corp. (ZOM.V) trades on the Canadian Venture Exchange (CVE) under the ticker symbol "ZOM."

How do I buy shares of Zomedica Pharmaceuticals Corp. (ZOM.V)?

Shares of ZOM stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Zomedica Pharmaceuticals Corp. (ZOM.V)'s stock price today?

One share of ZOM stock can currently be purchased for approximately C$0.29.

How much money does Zomedica Pharmaceuticals Corp. (ZOM.V) make?

Zomedica Pharmaceuticals Corp. (ZOM.V) (CVE:ZOM) has a market capitalization of C$36.73 million.

How can I contact Zomedica Pharmaceuticals Corp. (ZOM.V)?

The official website for the company is www.zomedica.com. The company can be reached via phone at 734-369-2555.

This page (CVE:ZOM) was last updated on 9/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.